Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to -$279000.0.

  • Arcadia Biosciences' Cash from Operations rose 8407.53% to -$279000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year increase of 4742.85%. This contributed to the annual value of -$9.6 million for FY2024, which is 3725.49% up from last year.
  • According to the latest figures from Q3 2025, Arcadia Biosciences' Cash from Operations is -$279000.0, which was up 8407.53% from -$2.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcadia Biosciences' Cash from Operations peaked at -$279000.0 during Q3 2025, and registered a low of -$8.3 million during Q3 2021.
  • Over the past 5 years, Arcadia Biosciences' median Cash from Operations value was -$3.4 million (recorded in 2022), while the average stood at -$3.6 million.
  • Per our database at Business Quant, Arcadia Biosciences' Cash from Operations plummeted by 7448.51% in 2023 and then skyrocketed by 8407.53% in 2025.
  • Arcadia Biosciences' Cash from Operations (Quarter) stood at -$6.7 million in 2021, then surged by 64.45% to -$2.4 million in 2022, then plummeted by 74.49% to -$4.2 million in 2023, then surged by 47.43% to -$2.2 million in 2024, then soared by 87.21% to -$279000.0 in 2025.
  • Its last three reported values are -$279000.0 in Q3 2025, -$2.0 million for Q2 2025, and -$1.6 million during Q1 2025.